Compare Amgen, Inc. (AMGN) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs FedEx Corporation — how do they compare? Amgen, Inc. trades at $416.31 (market cap $224.14B), while FedEx Corporation trades at $325.86 (market cap $76.28B). The key difference: Amgen, Inc. is far larger — about 2.9× FedEx Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | FDX | |
|---|---|---|
Market Cap | $224.14B | $76.28B |
Sector | Health | Industrials |
52-Week High | $417.20 | $338.75 |
52-Week Low | $271.18 | $180.51 |
Enterprise Value | $267.45B | $105.91B |
Dividend Yield | 2.43% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
FedEx (FDX) trades at $325.53, up 0.14% on the day, with a bullish technical signal and strong analyst backing. Recent earnings beats in Q4 2025 and Q1 2026, with EPS of $5.25 and $6.31 respectively against expectations, highlight operational strength. The company's Network 2.0 initiative aims for $2 billion in annual savings, supporting margin improvement. Valuation ratios like P/E of 17.38 and P/S of 0.81 appear reasonable relative to historical levels.
Outlook is positive with a consensus price target of $360.27, implying 11% upside, driven by cost-cutting and premium revenue shifts. Risks include softer freight demand and debt levels, but institutional buying and bullish sentiment suggest confidence in FedEx's execution amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
